ARTICLES BY YULIA PRIVOLNEV
-
![100 Dollar Bills scattered]( "What’s A Cure Worth? ICER Publishes Value Assessment Framework For Curative Therapies")
What’s A Cure Worth? ICER Publishes Value Assessment Framework For Curative Therapies8/27/2019The Institute for Clinical and Economic Review (ICER) recently conducted a study of value assessment methods considered for “cures” or “potential cures” and solicited input from international HTA bodies. The research will form the basis of a value framework that will be applied in the assessment of potential cures and other treatments that qualify as what ICER refers to as “single or short-term transformative therapies.”
-
![EU5-Map]( "CAR T-Cell Therapies In The EU5: What Can We Expect From Payers?")
CAR T-Cell Therapies In The EU5: What Can We Expect From Payers?1/24/2019The difficulty of balancing paying for innovation with budgets has plagued Europe for years, and the emergence of cell and gene therapies has only exacerbated that conundrum.
Yulia Privolnev
Yulia Privolnev is a manager on the Global Market Access Insights team at Decision Resources Group (DRG). She is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement (A&R) products. Privolnev's specific focus is on all aspects of market access in Western and Eastern Europe, as well as international reference pricing (IRP) and managed entry agreements (MEAs) on a global scale. She earned her M.A. from the London School of Economics.